|
| Monday, September 1, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
|
雲頂新耀發佈2025年中期業績：雙輪驅動戰略顯效 商業化與創新研發協同發力 |
| 雲頂新耀（01952.HK）公佈了截至2025年6月30日的中期業績報告中報顯示。公司實現收入人民幣4.46億元，同比增長48%；運營費用占收入比重大幅減少40.1個百分點，展現了卓越的運營效率。 more info >> |
|
|
云顶新耀发布2025年中期业绩：双轮驱动战略显效 商业化与创新研发协同发力 |
| 云顶新耀（01952.HK）公布了截至2025年6月30日的中期业绩报告中报显示。公司实现收入人民币4.46亿元，同比增长48%；运营费用占收入比重大幅减少40.1个百分点，展现了卓越的运营效率。 more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
|
艾曲莫德入選《2025 ACG臨床指南：成人潰瘍性結腸炎》，獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療 |
| 雲頂新耀今日宣布，旗下創新藥艾曲莫德（VELSIPITY(R)，etrasimod）被納入《2025 ACG 臨床指南：成人潰瘍性結腸炎》（下稱「新版指南」），並獲得強烈推薦用於中重度活動性潰瘍性潰瘍性結腸炎（UC）患者的誘導緩解及維持緩解治療（中等質量證據）。 more info >> |
|
|
艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗 |
| 云顶新耀今日宣布，旗下创新药艾曲莫德（VELSIPITY(R)，etrasimod）被纳入《2025 ACG 临床指南：成人溃疡性结肠炎》（下称"新版指南"），并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎（UC）患者的诱导缓解及维持缓解治疗（中等质量证据）。 more info >> |
|
| Thursday, August 14, 2025 |
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
| Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
|
雲頂新耀維長寧（艾曲莫德）在中國台灣新藥上市申請獲受理 亞洲市場准入再迎里程碑 |
| 雲頂新耀今日宣布，中國台灣地區藥政主管部門（TFDA）已正式受理維長寧（艾曲莫德，中國台灣地區商品名：「維長寧」）用於治療中重度活動性潰瘍性結腸炎（UC）患者的新藥上市許可申請（NDA）。 more info >> |
|
|
云顶新耀维长宁（艾曲莫德）在中国台湾新药上市申请获受理 亚洲市场准入再迎里程碑 |
| 云顶新耀今日宣布，中国台湾地区药政主管部门（TFDA）已正式受理维长宁（艾曲莫德，中国台湾地区商品名："維長寧"）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。 more info >> |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
|
|
|
